Cargando…
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
This randomised trial compared platinum-based to anthracycline-based chemotherapy in patients with small-cell lung cancer (limited or extensive stage) and ⩽2 adverse prognostic factors. Patients were randomised to receive six cycles of either ACE (doxorubicin 50 mg/m(2) i.v., cyclophosphamide 1 g/m(...
Autores principales: | Baka, S, Califano, R, Ferraldeschi, R, Aschroft, L, Thatcher, N, Taylor, P, Faivre-Finn, C, Blackhall, F, Lorigan, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527803/ https://www.ncbi.nlm.nih.gov/pubmed/18665190 http://dx.doi.org/10.1038/sj.bjc.6604480 |
Ejemplares similares
-
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
por: Blagden, Sarah P, et al.
Publicado: (2020) -
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
por: Lindemann, Kristina, et al.
Publicado: (2017) -
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017) -
Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021) -
Nimotuzumab plus platinum-based chemotherapy versus
platinum-based chemotherapy alone in patients with recurrent or metastatic
nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)